{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T07:10:59Z","timestamp":1790233859715,"version":"4.1.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2009,4,2]],"date-time":"2009-04-02T00:00:00Z","timestamp":1238630400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1007\/s00262-009-0700-0","type":"journal-article","created":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T13:18:57Z","timestamp":1238591937000},"page":"1887-1896","source":"Crossref","is-referenced-by-count":54,"title":["Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing"],"prefix":"10.1007","volume":"58","author":[{"given":"Timothy E.","family":"Kute","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"John R.","family":"Stehle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung W.","family":"Kim-Shapiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Blanks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James P.","family":"Vaughn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2009,4,2]]},"reference":[{"key":"700_CR1","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1158\/1535-7163.MCT-06-0766","volume":"6","author":"M Barok","year":"2007","unstructured":"Barok M, Isola J, Palyi-Krekk Z, Nagy P, Juhasz I, Vereb G, Kauraniemi P, Kapanen A, Tanner M, Vereb G, Szollosi J (2007) Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol Cancer Ther 6:2065\u20132072","journal-title":"Mol Cancer Ther"},{"key":"700_CR2","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1200\/JCO.2004.08.065","volume":"22","author":"H Burris III","year":"2004","unstructured":"Burris HIII, Yardley D, Jones S, Houston G, Broome C, Thompson D, Greco FA, White M, Hainsworth J (2004) Phase II trial of trastuzumab followed by weekly paclitaxel\/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 22:1621\u20131629","journal-title":"J Clin Oncol"},{"key":"700_CR3","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1200\/JCO.2003.03.124","volume":"21","author":"HJ Burstein","year":"2003","unstructured":"Burstein HJ, Harris LN, Gelman R, Lester SC, Nunes RA, Kaelin CM, Parker LM, Ellisen LW, Kuter I, Gadd MA, Christian RL, Kennedy PR, Borges VF, Bunnell CA, Younger J, Smith BL, Winer EP (2003) Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin\/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol 21:46\u201353","journal-title":"J Clin Oncol"},{"key":"700_CR4","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","volume":"89","author":"P Carter","year":"1992","unstructured":"Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (1992) Humanization of an anti-p185HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 89:4285\u20134289","journal-title":"Proc Natl Acad Sci USA"},{"key":"700_CR5","doi-asserted-by":"publisher","first-page":"2725","DOI":"10.1200\/JCO.2007.13.7729","volume":"26","author":"G Cartron","year":"2008","unstructured":"Cartron G, Zhao-Yang L, Baudard M, Kanouni T, Rouille V, Quittet P, Klein B, Rossi JF (2008) Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study. J Clin Oncol 26:2725\u20132731","journal-title":"J Clin Oncol"},{"key":"700_CR6","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrm1962","volume":"7","author":"A Citri","year":"2006","unstructured":"Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505\u2013516","journal-title":"Nat Rev Mol Cell Biol"},{"key":"700_CR7","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/74704","volume":"6","author":"RA Clynes","year":"2000","unstructured":"Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443\u2013446","journal-title":"Nat Med"},{"key":"700_CR8","unstructured":"Drugger DL, Hollingshead PG, Wong D, Romero M, Erickson SL, RH S (2002) Acquistion of Herceptin resistance by HER2 mutation in the HER2 transgenic mouse breast cancer model. Proceedings of the 93rd Annual Meeting of the American Association Cancer Research, San Francisco"},{"key":"700_CR9","doi-asserted-by":"publisher","first-page":"5650","DOI":"10.1158\/1078-0432.CCR-04-0225","volume":"10","author":"R Gennari","year":"2004","unstructured":"Gennari R, Menard S, Fagnoni F, Ponchio L, Scelsi M, Tagliabue E, Castiglioni F, Villani L, Magalotti C, Gibelli N, Oliviero B, Ballardini B, Da Prada G, Zambelli A, Costa A (2004) Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin Cancer Res 10:5650\u20135655","journal-title":"Clin Cancer Res"},{"key":"700_CR10","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1089\/adt.2006.4.555","volume":"4","author":"J Glamann","year":"2006","unstructured":"Glamann J, Hansen AJ (2006) Dynamic detection of natural killer cell-mediated cytotoxicity and cell adhesion by electrical impedance measurements. Assay Drug Dev Technol 4:555\u2013563","journal-title":"Assay Drug Dev Technol"},{"key":"700_CR11","first-page":"3384","volume":"60","author":"LN Klapper","year":"2000","unstructured":"Klapper LN, Waterman H, Sela M, Yarden Y (2000) Tumor-inhibitory antibodies to HER-2\/ErbB-2 may act by recruiting c-Cbl and enhancing ubiquitination of HER-2. Cancer Res 60:3384\u20133388","journal-title":"Cancer Res"},{"key":"700_CR12","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/cncr.11656","volume":"98","author":"KS Klos","year":"2003","unstructured":"Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D (2003) Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer 98:1377\u20131385","journal-title":"Cancer"},{"key":"700_CR13","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1158\/1078-0432.CCR-0385-3","volume":"10","author":"WJ Kostler","year":"2004","unstructured":"Kostler WJ, Schwab B, Singer CF, Neumann R, Rucklinger E, Brodowicz T, Tomek S, Niedermayr M, Hejna M, Steger GG, Krainer M, Wiltschke C, Zielinski CC (2004) Monitoring of serum Her-2\/neu predicts response and progression-free survival to trastuzumab-based treatment in patients with metastatic breast cancer. Clin Cancer Res 10:1618\u20131624","journal-title":"Clin Cancer Res"},{"key":"700_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/cyto.a.10095","volume":"57","author":"T Kute","year":"2004","unstructured":"Kute T, Lack CM, Willingham M, Bishwokama B, Williams H, Barrett K, Mitchell T, Vaughn JP (2004) Development of Herceptin resistance in breast cancer cells. Cytometry A 57:86\u201393","journal-title":"Cytometry A"},{"key":"700_CR15","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1023\/A:1012999012192","volume":"70","author":"S Mayfield","year":"2001","unstructured":"Mayfield S, Vaughn JP, Kute TE (2001) DNA strand breaks and cell cycle perturbation in herceptin treated breast cancer cell lines. Breast Cancer Res Treat 70:123\u2013129","journal-title":"Breast Cancer Res Treat"},{"key":"700_CR16","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccr.2004.06.022","volume":"6","author":"Y Nagata","year":"2004","unstructured":"Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117\u2013127","journal-title":"Cancer Cell"},{"key":"700_CR17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/0008-5472.473.65.2","volume":"65","author":"P Nagy","year":"2005","unstructured":"Nagy P, Friedlander E, Tanner M, Kapanen AI, Carraway KL, Isola J, Jovin TM (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65:473\u2013482","journal-title":"Cancer Res"},{"key":"700_CR18","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1038\/sj.onc.1210379","volume":"26","author":"R Nahta","year":"2007","unstructured":"Nahta R, Esteva FJ (2007) Trastuzumab: triumphs and tribulations. Oncogene 26:3637\u20133643","journal-title":"Oncogene"},{"key":"700_CR19","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/978-1-59745-467-4_2","volume":"412","author":"WM Nauseef","year":"2007","unstructured":"Nauseef WM (2007) Isolation of human neutrophils from venous blood. Methods Mol Biol 412:15\u201320","journal-title":"Methods Mol Biol"},{"key":"700_CR20","doi-asserted-by":"publisher","first-page":"1659","DOI":"10.1056\/NEJMoa052306","volume":"353","author":"MJ Piccart-Gebhart","year":"2005","unstructured":"Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659\u20131672","journal-title":"N Engl J Med"},{"key":"700_CR21","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1002\/ijc.10410","volume":"99","author":"SA Price-Schiavi","year":"2002","unstructured":"Price-Schiavi SA, Jepson S, Li P, Arango M, Rudland PS, Yee L, Carraway KL (2002) Rat Muc4 (sialomucin complex) reduces binding of anti-ErbB2 antibodies to tumor cell surfaces, a potential mechanism for herceptin resistance. Int J Cancer 99:783\u2013791","journal-title":"Int J Cancer"},{"key":"700_CR22","first-page":"2440","volume":"9","author":"T Repka","year":"2003","unstructured":"Repka T, Chiorean EG, Gay J, Herwig KE, Kohl VK, Yee D, Miller JS (2003) Trastuzumab and interleukin-2 in HER2-positive metastatic breast cancer: a pilot study. Clin Cancer Res 9:2440\u20132446","journal-title":"Clin Cancer Res"},{"key":"700_CR23","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1056\/NEJM200103153441101","volume":"344","author":"DJ Slamon","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783\u2013792","journal-title":"N Engl J Med"},{"key":"700_CR24","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1089\/adt.2004.2.363","volume":"2","author":"K Solly","year":"2004","unstructured":"Solly K, Wang X, Xu X, Strulovici B, Zheng W (2004) Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. Assay Drug Dev Technol 2:363\u2013372","journal-title":"Assay Drug Dev Technol"},{"key":"700_CR25","first-page":"1720","volume":"8","author":"CI Spiridon","year":"2002","unstructured":"Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL, Vitetta ES (2002) Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8:1720\u20131730","journal-title":"Clin Cancer Res"},{"key":"700_CR26","doi-asserted-by":"publisher","first-page":"3542","DOI":"10.1158\/1078-0432.CCR-03-0549","volume":"10","author":"CI Spiridon","year":"2004","unstructured":"Spiridon CI, Guinn S, Vitetta ES (2004) A comparison of the in vitro and in vivo activities of IgG and F(ab\u2032)2 fragments of a mixture of three monoclonal anti-Her-2 antibodies. Clin Cancer Res 10:3542\u20133551","journal-title":"Clin Cancer Res"},{"key":"700_CR27","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1158\/1535-7163.1585.3.12","volume":"3","author":"M Tanner","year":"2004","unstructured":"Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, Elenius K, Isola J (2004) Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther 3:1585\u20131592","journal-title":"Mol Cancer Ther"},{"key":"700_CR28","doi-asserted-by":"publisher","first-page":"11991","DOI":"10.1158\/0008-5472.CAN-07-2068","volume":"67","author":"S Varchetta","year":"2007","unstructured":"Varchetta S, Gibelli N, Oliviero B, Nardini E, Gennari R, Gatti G, Silva LS, Villani L, Tagliabue E, Menard S, Costa A, Fagnoni FF (2007) Elements related to heterogeneity of antibody-dependent cell cytotoxicity in patients under trastuzumab therapy for primary operable breast cancer overexpressing Her2. Cancer Res 67:11991\u201311999","journal-title":"Cancer Res"},{"key":"700_CR29","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1200\/JCO.20.3.719","volume":"20","author":"CL Vogel","year":"2002","unstructured":"Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ, Press M (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20:719\u2013726","journal-title":"J Clin Oncol"},{"key":"700_CR30","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1021\/tx049721s","volume":"18","author":"JZ Xing","year":"2005","unstructured":"Xing JZ, Zhu L, Jackson JA, Gabos S, Sun XJ, Wang XB, Xu X (2005) Dynamic monitoring of cytotoxicity on microelectronic sensors. Chem Res Toxicol 18:154\u2013161","journal-title":"Chem Res Toxicol"},{"key":"700_CR31","first-page":"4132","volume":"62","author":"FM Yakes","year":"2002","unstructured":"Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62:4132\u20134141","journal-title":"Cancer Res"},{"key":"700_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.jim.2005.10.018","volume":"309","author":"J Zhu","year":"2006","unstructured":"Zhu J, Wang X, Xu X, Abassi YA (2006) Dynamic and label-free monitoring of natural killer cell cytotoxic activity using electronic cell sensor arrays. J Immunol Methods 309:25\u201333","journal-title":"J Immunol Methods"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-009-0700-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-009-0700-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-009-0700-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-009-0700-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T18:21:30Z","timestamp":1684952490000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-009-0700-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4,2]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["700"],"URL":"https:\/\/doi.org\/10.1007\/s00262-009-0700-0","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4,2]]}}}